home / stock / trvn / trvn quote
Last: | $0.3652 |
---|---|
Change Percent: | -9.15% |
Open: | $0.4225 |
Close: | $0.402 |
High: | $0.43 |
Low: | $0.3625 |
Volume: | 1,151,197 |
Last Trade Date Time: | 04/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.3652 | $0.4225 | $0.402 | $0.43 | $0.3625 | 1,151,197 | 04-18-2024 |
$0.402 | $0.38 | $0.402 | $0.41 | $0.3727 | 3,658,634 | 04-17-2024 |
$0.393 | $0.39 | $0.393 | $0.403 | $0.371 | 73,078 | 04-16-2024 |
$0.391854 | $0.379 | $0.391854 | $0.42 | $0.379 | 68,077 | 04-15-2024 |
$0.3814 | $0.419 | $0.3814 | $0.419 | $0.37 | 184,033 | 04-12-2024 |
$0.413 | $0.4098 | $0.413 | $0.42 | $0.4055 | 44,884 | 04-11-2024 |
$0.406 | $0.4054 | $0.406 | $0.42 | $0.4007 | 89,064 | 04-10-2024 |
$0.4003 | $0.41 | $0.4003 | $0.4249 | $0.4 | 81,019 | 04-09-2024 |
$0.4113 | $0.417 | $0.4113 | $0.423931 | $0.39 | 35,127 | 04-08-2024 |
$0.417 | $0.404 | $0.417 | $0.42 | $0.399 | 82,577 | 04-05-2024 |
$0.396 | $0.39 | $0.396 | $0.4099 | $0.39 | 112,866 | 04-04-2024 |
$0.379 | $0.3995 | $0.379 | $0.413699 | $0.3625 | 238,949 | 04-03-2024 |
$0.3713 | $0.4 | $0.3713 | $0.4 | $0.3001 | 353,545 | 04-02-2024 |
$0.4 | $0.4556 | $0.4 | $0.46 | $0.39 | 421,781 | 04-01-2024 |
$0.46 | $0.49 | $0.46 | $0.49 | $0.45 | 141,813 | 03-29-2024 |
$0.46 | $0.49 | $0.46 | $0.49 | $0.45 | 141,813 | 03-28-2024 |
$0.4586 | $0.456 | $0.4586 | $0.4625 | $0.44 | 68,134 | 03-27-2024 |
$0.4433 | $0.436 | $0.4433 | $0.471425 | $0.431 | 134,380 | 03-26-2024 |
$0.435 | $0.454 | $0.435 | $0.4699 | $0.4212 | 95,381 | 03-25-2024 |
$0.46 | $0.509 | $0.46 | $0.509 | $0.4068 | 371,904 | 03-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
2024-04-02 07:15:05 ET JMP Securities analyst issues MARKET OUTPERFORM recommendation for TRVN on April 2, 2024 05:40AM ET. The previous analyst recommendation was Market Outperform. TRVN was trading at $0.4 at issue of the analyst recommendation. Historical Analyst Re...
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company announces reduction of OLINVYK commercial support and review of alternatives for OLINVYK CHESTERBROOK, Pa., April 01, 2024 (GL...
CHESTERBROOK, Pa., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. ("Trevena" or the "Company") (NASDAQ:TRVN), a biopharmaceutical company focus...